<DOC>
	<DOC>NCT00048750</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy and safety of intravenous micafungin versus placebo as prophylactic therapy for invasive fungal infections in patients in the intensive care unit considered to be at high risk.</brief_summary>
	<brief_title>Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Inclusion Criteria Meets entry criteria for high risk Exclusion Criteria Evidence of active invasive fungal infection Received more than one dose of systemic antifungal agent within 72 hours prior to first dose of study drug Known to be HIV positive who have CD4 count less than 500 cells/mm3 Has lifeexpectancy of less than 72 hours or moribund</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Anti-Fungal Therapy</keyword>
	<keyword>Preemptive Anti-Fungal Therapy</keyword>
	<keyword>Invasive Fungal Infection</keyword>
	<keyword>Micafungin</keyword>
	<keyword>ICU</keyword>
</DOC>